Skip to main content
Midas Edge

Sana Biotechnology Inc

For the period ended Sep 30, 2024. Filed Nov 8, 2024.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2024 · Filed Nov 8, 2024

SANA$2.43-1.4%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

Condensed Consolidated Statements of Stockholders’ Equity

Common Stock · AdditionalPaid-In · AccumulatedOtherComprehensive · Accumulated · TotalStockholders'
SharesAmountCapitalIncome (Loss)DeficitEquity
Balance as of December 31, 2023197,857$20$1,625,637$(60)$(1,338,091)$287,506
Issuance of common stock from at the market offering, net of issuance costs of $113150-1,037--1,037
Issuance of common stock from follow-on offering and accompanying pre-funded warrants, net of issuance costs of $9,74121,7732180,006--180,008
Vesting of restricted stock386-----
Exercise of stock options1,120-4,929--4,929
Stock-based compensation expense--9,092--9,092
Unrealized gain on marketable securities, net---45-45
Net loss----(107,475)(107,475)
Balance as of March 31, 2024221,286$22$1,820,701$(15)$(1,445,566)$375,142
Fees incurred related to common stock financings--(16)--(16)
Vesting of restricted stock52-----
Exercise of stock options548-2,361--2,361
Issuance of common stock related to employee stock purchase plan323-1,077--1,077
Stock-based compensation expense--11,380--11,380
Unrealized loss on marketable securities, net---(4)-(4)
Net loss----(50,291)(50,291)
Balance as of June 30, 2024222,209$22$1,835,503$(19)$(1,495,857)$339,649
Fees incurred related to common stock financings--(29)--(29)
Vesting of restricted stock84-----
Exercise of stock options815-1,939--1,939
Stock-based compensation expense--10,770--10,770
Unrealized gain on marketable securities, net---73-73
Net loss----(59,924)(59,924)
Balance as of September 30, 2024223,108$22$1,848,183$54$(1,555,781)$292,478
Common Stock · AdditionalPaid-In · AccumulatedOtherComprehensive · Accumulated · Total Stockholders'
SharesAmountCapitalLossDeficitEquity
Balance as of December 31, 2022191,022$19$1,558,459$(4,327)$(1,054,836)$499,315
Fees incurred related to issuance of common stock from at the market offering--(200)--(200)
Vesting of restricted stock154-----
Exercise of stock options233-331--331
Stock-based compensation expense--8,751--8,751
Unrealized gain on marketable securities, net---2,188-2,188
Net loss----(82,123)(82,123)
Balance as of March 31, 2023191,409$19$1,567,341$(2,139)$(1,136,959)$428,262
Issuance of common stock from at the market offering, net of issuance costs of $9854,586127,247--27,248
Vesting of restricted stock119-----
Exercise of stock options357-691--691
Issuance of common stock related to employee stock purchase plan409-1,705--1,705
Stock-based compensation expense--9,848--9,848
Unrealized gain on marketable securities, net---1,274-1,274
Net loss----(113,999)(113,999)
Balance as of June 30, 2023196,880$20$1,606,832$(865)$(1,250,958)$355,029
Fees incurred related to issuance of common stock from at the market offering--(19)--(19)
Vesting of restricted stock81-----
Exercise of stock options103-192--192
Stock-based compensation expense--9,003--9,003
Unrealized gain on marketable securities, net---663-663
Net income----984984
Balance as of September 30, 2023197,064$20$1,616,008$(202)$(1,249,974)$365,852
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.